Contract 75A50122C00065
Amgen USA Inc · Department Of Health And Human Services · September 28, 2022
Amgen USA Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 28, 2022 for $773.88 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Newbury Park, CA. It was awarded under full and open competition. The contract has been modified 7 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 6, 2026.
Contract details
- PIID
- 75A50122C00065
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Experimental Development
- Place of performance
- Newbury Park, CA
- First action
- September 28, 2022
- Latest action
- March 6, 2026
Description
EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED VALUE INCREASED FROM $713,890,168.42 BY
Modification timeline
-
March 6, 2026Mod P00007EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED$59.99M
-
July 15, 2025Mod P00006EXERCISE OPTION PERIOD 3 CLINS 0010, 0011, AND 0012.$89.98M
-
September 27, 2024Mod P00005REVISE OPTION PERIOD 2 CLINS 0007 - 0009 PERIOD OF PERFORMANCE.$0
-
September 18, 2024Mod P00004EXERCISE OPTION PERIOD 2 CLINS 0007 - 0009 FOR THE PROCUREMENT OF 62,896 UNITS OF NPLATE PHARMACEUTICAL PRODUCTS.$129.00M
-
February 5, 2024Mod P00003NO COST MODIFICATION TO REVISE SECTION B.2.2, CLIN TABLE DESCRIPTION COLUMN FOR CLIN0005.$0
-
September 20, 2023Mod P00002AMGEN - EXERCISE OPTIONAL CLINS 0004, 0005, AND 0006. ADD FAR CLAUSE 52.204-27.$204.86M
-
December 12, 2022Mod P00001AMGEN - UNILATERAL MODIFICATION TO REVISE THE CONTRACTING OFFICER.$0
-
September 28, 2022Base awardTREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.$290.06M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | The Boeing Company | 1 | $4.44B |
| 2 | Advanced Technology International | 9 | $3.35B |
| 3 | Amgen USA Inc | 2 | $774.69M |
| 4 | Siga Technologies, Inc. | 1 | $624.44M |
| 5 | Icon Government And Public Health Solutions, Inc. | 16 | $404.80M |
| 6 | Technical Resources International, Inc. | 19 | $395.29M |
| 7 | Allucent Government Services (Us) Llc | 9 | $384.26M |
| 8 | Mapp Biopharmaceutical, Inc. | 7 | $354.24M |
| 9 | Ppd Development Lp | 18 | $331.02M |
| 10 | Albert B. Sabin Vaccine Institute, Inc. (The) | 2 | $305.87M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50122C00065?
Contract 75A50122C00065 is a federal contract awarded to Amgen USA Inc by Department Of Health And Human Services on September 28, 2022 for $773.88 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 7 times since the base award.
Who won contract 75A50122C00065?
Amgen USA Inc won contract 75A50122C00065 from Department Of Health And Human Services.
How much is contract 75A50122C00065 worth?
Contract 75A50122C00065 has obligated $773.88 million to date, with a total potential value of $916.70 million if all options are exercised.